At onset, Crohn’s disease (CD) is characterized by transmural inflammation with mucosal ulcerations. In its earliest phase the lesions are mainly aphthous ulcers. The ulcers then become larger, a nodular pattern develops and penetration of the deep ulcers leads to fistulas and collagen deposition to fibrotic strictures. The best model to study the earliest lesions in CD is the postoperative recurrence situation where these early lesions recur within weeks to months after surgery. CD recurrence is triggered by the fecal contents of the gut since temporary diversion prevents the recurrence of bowel inflammation. With the development of newer techniques, such as microarray analysis of total mucosal gene expression and molecular analysis of gut content and mucosal microbiome, this model will allow to shed light on the earliest pathogenic features of CD.

Keywords:
Aphthous ulcer, Full-blown Crohnߣs disease, Crohnߣs disease recurrence, Early tissue lesions, prevention, Endoscopic recurrence score, Postoperative recurrence model
1.
Rutgeerts P, Geboes K: Crohn’s disease and pre-aphthoid lesions. Lancet 1993;341:1443–1444.
2.
Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G: Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665–672.
3.
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990;99:956–963.
4.
Rutgeerts P, Geboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R: Effect of fecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991;338:771–774.
5.
D’Haens G, Geboes K, Peeters M, Baert F, Penninckx F: Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262–267.
6.
Ferrante M, De Hertogh G, Hlavaty T, D’Haens G, Penninckx F, D’Hoore A, Vermeire S, Rutgeerts P, Geboes K, Van Assche G: The value of myenteric plexitis to predict early postoperative Crohn’s disease recurrence. Gastroenterology 2006;130:1595–1606.
7.
Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P: Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009;58:1612–1619.
8.
Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, Leemans P, Cleynen I, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P: Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 2009;24;4:e7984.
9.
Joossens M, Huys G, Cnockaert M, Van Steen K, Vermeire S, Rutgeerts P, Verbeke K, Vandamme P, De Preter V: Statistical analysis of complex PCR-DGGE profiles from human fecal samples taking detection-limit bias into account. FEMS Microbiol Lett 2011;75:343–349.
10.
Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R: Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995;108:1617–1621.
11.
Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D’Hoore A, Penninckx F: Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856–861.
12.
D’Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P: Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology 2008;135:1123–1129.
13.
Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE: Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009;136:441–450.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.